Skip to Content
Merck

C1335

S-(−)-Carbidopa

≥98% (TLC), powder

Synonym(s):

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid, S-(−)-α-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H14N2O4
CAS Number:
28860-95-9
Molecular Weight:
226.23
NACRES:
NA.77
PubChem Substance ID:
24892402
UNSPSC Code:
12352202
EC Number:
249-271-9
MDL number:
MFCD00069231

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

S-(−)-Carbidopa, ≥98% (TLC), powder

InChI key

TZFNLOMSOLWIDK-JTQLQIEISA-N

InChI

1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

SMILES string

CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O

assay

≥98% (TLC)

form

powder

solubility

methanol and 1 drop HCl: 4.90-5.10 mg/mL, clear, colorless to faintly yellow

storage temp.

−20°C

Quality Level

200

Gene Information

human ... DDC(1644)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase.
Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.

General description

Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000133058
0000133058
0000397928
0000397928
0000290557

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients
Earley CJ and Allen RP
Sleep, 19(10), 801-810 (1996)
Levodopa with benserazide or carbidopa in Parkinson disease
Rinne UK and Molsa P
Neurology, 29(12), 1584-1589 (1979)
Extended-release carbidopa-levodopa in Parkinson's disease.
Olivier Rascol
The Lancet. Neurology, 12(4), 325-326 (2013-03-15)
Venkatraman Junnotula et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 926, 47-53 (2013-04-04)
A simple, selective, and sensitive quantitative method has been developed for the simultaneous determination of levodopa and carbidopa in rat and monkey plasma by protein precipitation using acetonitrile containing the derivatizing reagent, flourescamine. Derivatized products of levodopa and carbidopa were
V K Datieva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 13-19 (2012-12-20)
The objective of this multicenter observational study "Optimization levodopa therapy for patients with Parkinson's disease" (OPTIMA) was to evaluate the current practice of prescribing levodopa to patients with Parkinson's disease (PD) by general practitioners and specialists in the treatment of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service